Anti-vascular endothelial growth factors in combination with vitrectomy for complications of proliferative diabetic retinopathy

医学 玻璃体切除术 糖尿病性视网膜病变 围手术期 视力 外科 眼科 糖尿病 内分泌学
作者
Panagiotis Dervenis,Nikolaos Dervenis,Jonathan Smith,David Steel
出处
期刊:The Cochrane library [Elsevier]
卷期号:2023 (5) 被引量:8
标识
DOI:10.1002/14651858.cd008214.pub4
摘要

Background Vitrectomy is an established treatment for the complications of proliferative diabetic retinopathy (PDR). However, a number of complications can occur during and after vitrectomy for PDR. These include bleeding and the creation of retinal holes during surgery, and bleeding, retinal detachment and scar tissue on the retina after surgery. These complications can limit vision, require further surgery and delay recovery. The use of anti‐vascular endothelial growth factor (anti‐VEGF) agents injected into the eye before surgery has been proposed to reduce the occurrence of these complications. Anti‐VEGF agents can reduce the amount and vascularity of abnormal new vessels associated with PDR, facilitating their dissection during surgery, reducing intra‐ and postoperative bleeding, and potentially improving outcomes. Objectives To assess the effects of perioperative anti‐VEGF use on the outcomes of vitrectomy for the treatment of complications for proliferative diabetic retinopathy (PDR). Search methods We searched the Cochrane Central Register of Controlled Trials (CENTRAL; which contains the Cochrane Eyes and Vision Trials Register; 2022, Issue 6); Ovid MEDLINE; Ovid Embase; the ISRCTN registry; ClinicalTrials.gov and the WHO ICTRP. The date of the search was 22 June 2022. Selection criteria We included randomised controlled trials (RCTs) that looked at the use of anti‐VEGFs and the incidence of complications in people undergoing vitrectomy for PDR. Data collection and analysis Two review authors independently assessed and extracted the data. We used the standard methodological procedures expected by Cochrane. The critical outcomes of the review were the mean difference in best corrected visual acuity (BCVA) between study arms at six (± three) months after the primary vitrectomy, the incidence of early postoperative vitreous cavity haemorrhage (POVCH, within four weeks postoperatively), the incidence of late POVCH (occurring more than four weeks postoperatively), the incidence of revision surgery for POVCH within six months, the incidence of revision surgery for recurrent traction/macular pucker of any type and/or rhegmatogenous retinal detachment within six months and vision‐related quality of life (VRQOL) measures. Important outcomes included the proportion of people with a visual acuity of counting fingers (1.8 logMAR or worse), the number of operative retinal breaks reported and the frequency of silicone oil tamponade required at time of surgery. Main results The current review includes 28 RCTs that looked at the pre‐ or intraoperative use of intravitreal anti‐VEGFs to improve the outcomes of pars plana vitrectomy for complications of PDR. The studies were conducted in a variety of countries (11 from China, three from Iran, two from Italy, two from Mexico and the remaining studies from South Korea, the UK, Egypt, Brazil, Japan, Canada, the USA, Indonesia and Pakistan). The inclusion criteria for entry into the studies were the well‐recognised complications of proliferative retinopathy: non‐clearing vitreous haemorrhage, tractional retinal detachment involving the macula or combined tractional rhegmatogenous detachment. The included studies randomised a total of 1914 eyes. We identified methodological issues in all of the included studies. Risk of bias was highest for masking of participants and investigators, and a number of studies were unclear when describing randomisation methods and sequence allocation. Participants receiving intravitreal anti‐VEGF in addition to pars plana vitrectomy achieved better BCVA at six months compared to people undergoing vitrectomy alone (mean difference (MD) ‐0.25 logMAR, 95% confidence interval (CI) ‐0.39 to ‐0.11; 13 studies, 699 eyes; low‐certainty evidence). Pre‐ or intraoperative anti‐VEGF reduced the incidence of early POVCH (12% versus 31%, risk ratio (RR) 0.44, 95% CI 0.34 to 0.58; 14 studies, 1038 eyes; moderate‐certainty evidence). Perioperative anti‐VEGF use was also associated with a reduction in the incidence of late POVCH (10% versus 23%, RR 0.47, 95% CI 0.30 to 0.74; 11 studies, 579 eyes; high‐certainty evidence). The need for revision surgery for POVCH occurred less frequently in the anti‐VEGF group compared with control, but the confidence intervals were wide and compatible with no effect (4% versus 13%, RR 0.44, 95% CI 0.15 to 1.28; 4 studies 207 eyes; moderate‐certainty evidence). Similar imprecisely measured effects were seen for revision surgery for rhegmatogenous retinal detachment (5% versus 11%, RR 0.50, 95% CI 0.15 to 1.66; 4 studies, 145 eyes; low‐certainty evidence). Anti‐VEGFs reduce the incidence of intraoperative retinal breaks (12% versus 31%, RR 0.37, 95% CI 0.24 to 0.59; 12 studies, 915 eyes; high‐certainty evidence) and the need for silicone oil (19% versus 41%, RR 0.46, 95% CI 0.27 to 0.80; 10 studies, 591 eyes; very low‐certainty evidence). No data were available on quality of life outcomes or the proportion of participants with visual acuity of counting fingers or worse. Authors' conclusions The perioperative use of anti‐VEGF reduces the risk of late POVCH, probably results in lower early POVCH risk and may improve visual outcomes. It also reduces the incidence of intraoperative retinal breaks. The evidence is very uncertain about its effect on the need for silicone oil tamponade. The reported complications from its use appear to be low. Agreement on variables included and outcome standardisation is required in trials studying vitrectomy for PDR.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
英姑应助普鲁卡因采纳,获得10
2秒前
冰糕发布了新的文献求助10
4秒前
BettyNie完成签到 ,获得积分10
6秒前
优雅的平安完成签到 ,获得积分10
6秒前
冰糕完成签到,获得积分10
11秒前
13秒前
852应助完犊子采纳,获得10
17秒前
ruochenzu发布了新的文献求助10
18秒前
不想洗碗完成签到 ,获得积分10
20秒前
const完成签到,获得积分10
24秒前
hjx完成签到 ,获得积分10
24秒前
稳重的尔安完成签到,获得积分10
26秒前
量子星尘发布了新的文献求助10
27秒前
缓慢的饼干完成签到 ,获得积分10
27秒前
saturn完成签到 ,获得积分10
27秒前
金桔希子完成签到,获得积分10
28秒前
Breeze完成签到 ,获得积分10
28秒前
28秒前
昏睡的眼神完成签到 ,获得积分10
29秒前
文心同学完成签到,获得积分0
30秒前
demom完成签到 ,获得积分10
32秒前
duckspy完成签到 ,获得积分10
32秒前
完犊子发布了新的文献求助10
34秒前
普鲁卡因发布了新的文献求助30
35秒前
chenkj完成签到,获得积分10
37秒前
EricSai完成签到,获得积分10
37秒前
ikun完成签到,获得积分10
37秒前
李李发布了新的文献求助10
37秒前
章鱼小丸子完成签到 ,获得积分10
37秒前
byby完成签到,获得积分10
39秒前
THEO完成签到 ,获得积分10
40秒前
李健的小迷弟应助完犊子采纳,获得10
41秒前
42秒前
乐观的问兰完成签到 ,获得积分10
43秒前
书生完成签到,获得积分10
43秒前
朱佳宁完成签到 ,获得积分10
44秒前
Master完成签到 ,获得积分10
45秒前
怕孤独的香菇完成签到 ,获得积分10
45秒前
光亮冬寒完成签到,获得积分10
46秒前
FashionBoy应助李李采纳,获得10
47秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038112
求助须知:如何正确求助?哪些是违规求助? 3575788
关于积分的说明 11373801
捐赠科研通 3305604
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022